Abstract
Background and study aims: Reports have found an association between B cell non-Hodgkin lymphomas (NHL) and Hepatitis C virus (HCV) infection. However, data on acute exacerbation and reactivation of chronic HCV infection following chemotherapy are very limited. We studied the efficacy of ribavirin to prevent hepatitis reactivation in HCVinfected patients treated for NHL. Patients and methods: This study was
Highlights
Hepatitis C virus (HCV) infection is endemic in Egypt
The percentage of HCV infection among B cell non-Hodgkin lymphomas (NHL) patients is 42 % (24 out of 57 cases) which is in agreement with and equal to results obtained by Cowgill et al.[10], while Coppola et al [11]
This comes in agreement with Nosotti et al [3], who stated that the prevalence of HCV infection among NHL patients was 9.2%, this prevalence is higher than that observed in the general population in Italy (3%)
Summary
Many reports have found an association between B cell non-Hodgkin lymphomas (NHL) and HCV infection. Authors have reported a reactivation of HCV replication in patients with CD20positive B-cell NHL under Rituximab-based chemotherapy [4]. In analogy with the use of lamivudine as prophylaxis against HBV reactivation, we tried to use Ribavirin (a synthetic nucleoside analogue) as a prophylactic antiviral treatment to reduce the risk of HCV reactivation and severe hepatitis flares. The study is a randomized controlled intervention trial, that was carried out at Medical Oncology and Hematology Department , Zagazig University Hospitals between July 2010 and August 2012 It included 57 patients with NHL who were naïve to chemotherapy, among them 24 patients were positive for HCV infection & 33 patients were negative for HCV infection (group C).
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Afro-Egyptian Journal of Infectious and Endemic Diseases
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
